Life's simple measures: unlocking the proteome.
暂无分享,去创建一个
Rachel Ostroff | Larry Gold | L. Gold | Jeffrey J. Walker | D. Zichi | E. Brody | M. Mehan | R. Ostroff | J. Rohloff | Edward Brody | Mike Mehan | Dom Zichi | John Rohloff | Jeff Walker
[1] Tracy R. Keeney,et al. From SOMAmer-Based Biomarker Discovery to Diagnostic and Clinical Applications: A SOMAmer-Based, Streamlined Multiplex Proteomic Assay , 2011, PloS one.
[2] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[3] Stephen A. Williams,et al. Unlocking Biomarker Discovery: Large Scale Application of Aptamer Proteomic Technology for Early Detection of Lung Cancer , 2010, PloS one.
[4] Rachel Ostroff,et al. The stability of the circulating human proteome to variations in sample collection and handling procedures measured with an aptamer-based proteomics array. , 2010, Journal of proteomics.
[5] M. Okada,et al. Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. , 2005, The Journal of thoracic and cardiovascular surgery.
[6] Dan Schneider,et al. Expanding the chemistry of DNA for in vitro selection. , 2010, Journal of the American Chemical Society.
[7] Larry Gold,et al. High-content affinity-based proteomics: unlocking protein biomarker discovery , 2010, Expert review of molecular diagnostics.
[8] Stephen Quake,et al. Enhanced signals and fast nucleic acid hybridization by microfluidic chaotic mixing. , 2006, Angewandte Chemie.
[9] Rachel Ostroff,et al. Highly multiplexed proteomic platform for biomarker discovery, diagnostics, and therapeutics. , 2013, Advances in experimental medicine and biology.
[10] B. Stewart,et al. World Cancer Report , 2003 .
[11] Tracy R. Keeney,et al. Aptamer-based multiplexed proteomic technology for biomarker discovery , 2010, Nature Precedings.
[12] Alex Stewart,et al. Automation of the SomaLogic Proteomics Assay: A Platform for Biomarker Discovery , 2009 .
[13] H. Pass,et al. Current status of screening for malignant pleural mesothelioma. , 2009, Seminars in thoracic and cardiovascular surgery.
[14] R. Wehrens. Chemometrics with R , 2020, Use R!.
[15] L. Dwyer-Nield,et al. A macrophage gene expression signature defines a field effect in the lung tumor microenvironment. , 2008, Cancer research.
[16] John D. Storey. A direct approach to false discovery rates , 2002 .
[17] L. Tanoue. Cancer Statistics, 2009 , 2010 .
[18] L. Gold,et al. Oligonucleotides as Research, Diagnostic, and Therapeutic Agents(*) , 1995, The Journal of Biological Chemistry.
[19] L. Gold,et al. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.
[20] Sheri K. Wilcox,et al. Protein Signature of Lung Cancer Tissues , 2012, PloS one.
[21] Marc Madou,et al. Microfluidic device for rapid (<15 min) automated microarray hybridization. , 2005, Clinical chemistry.
[22] J. Szostak,et al. In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.